調査レポートカテゴリー： MarketsandMarkets, 世界, 医療/バイオ

Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024

ワクチンの世界市場予測：技術別（生、トキソイド、組換え）、疾患別（肺炎球菌、インフルエンザ、DTP、ロタウイルス、TT、ポリオ、MMR、水痘、デング熱、結核、帯状疱疹、狂犬病）、経路別（IM、SC、ID、経口）、患者別（小児、成人）、種類別

◆タイトル：Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024
◆商品コード：PH 6528
◆調査・発行会社：MarketsandMarkets
◆発行日：2020年1月29日
◆ページ数：189
◆レポート形式：PDF / 英語
◆納品方法：Eメール（受注後24時間以内）
◆調査対象地域：グローバル
◆産業分野：医薬品
◆販売価格オプション（消費税別）
Single User（1名様閲覧）USD5,650 ⇒換算￥0見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算￥0見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算￥0見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。（但し、対応範囲は弊社で判断）
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

 【レポートの概要】

MarketsandMarkets社は核医学/放射性医薬品の世界市場が、2019年41億ドルから2024年52憶ドルまで、年平均4.7％成長すると予測しています。本調査レポートでは、核医学/放射性医薬品の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場動向、業界洞察、技術別（生、トキソイド、組換え）分析、病気徴候別（肺炎球菌疾患、DTP、インフルエンザ、HPV、髄膜炎菌性疾患、その他）分析、投与経路別（筋肉内＆皮下投与、その他）分析、患者別（小児、成人）分析、地域別分析、競争状況、企業概要などを含め、次の構成でお届け致します。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場動向
・業界洞察
・核医学/放射性医薬品の世界市場：技術別（生、トキソイド、組換え）
・核医学/放射性医薬品の世界市場：病気徴候別（肺炎球菌疾患、DTP、インフルエンザ、HPV、髄膜炎菌性疾患、その他）
・核医学/放射性医薬品の世界市場：投与経路別（筋肉内＆皮下投与、その他）
・核医学/放射性医薬品の世界市場：患者別（小児、成人）
・核医学/放射性医薬品の世界市場：地域別
・競争状況
・企業概要

“The vaccines market is projected to grow at a CAGR of 7.0% during the forecast period (2019–2024).”
The global vaccines market is projected to reach USD 58.4 billion by 2024 from USD 41.7 billion in 2019, at a CAGR of 7.0% during the forecast period. The key factors driving the growth of this market include the high prevalence of infectious diseases, growing support for vaccine R&D, investments in vaccine development, and rising focus on immunization. However, the huge capital investments required for developing vaccines may restrain market growth.

“The pneumococcal disease segment will continue to dominate the vaccines market during the forecast period.”
On the basis of disease indication, the vaccines market is segmented into pneumococcal disease, influenza, DTP, hepatitis, human papillomavirus (HPV), rotavirus, meningococcal disease, MMR (measles, mumps, and rubella), varicella, polio, herpes zoster, and other disease indications. The pneumococcal disease segment accounted for the largest share of the vaccines market in 2018. The large share of this segment can be attributed to the high incidence of pneumococcal disease and increasing government investments in pneumococcal vaccination programs.

“By type, the monovalent vaccines segment accounted for the larger share of the vaccines market in 2019.”
On the basis of type, the vaccines market is segmented into monovalent and multivalent vaccines. The monovalent vaccines segment accounted for the largest share of the vaccines market in 2018. The large share of this segment can be attributed to the rising prevalence of diseases and increasing government & non-government initiatives to promote immunization.

“The market in Asia is projected to witness the highest growth rate during the forecast period (2019–2024).”
Asia is projected to register the highest growth during the forecast period. Growing company investments in Asian countries and rising government support for vaccine development are some of the key factors supporting the growth of the vaccines market in Asia.

A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1: 47%, Tier 2: 26%, and Tier 3: 27%
• By Designation: C-level: 33%, Director-level: 21%, and Others: 46%
• By Region: North America: 36%, Europe: 31%, Asia: 16%, and the RoW: 17%

GlaxoSmithKline plc (UK), Pfizer, Inc. (US), Sanofi Pasteur (France), and Merck & Co., Inc. (US) are the leading players in the global vaccines market. Other notable players in this market include CSL Limited (Australia), Emergent BioSolutions, Inc. (US), Johnson & Johnson (US), AstraZeneca (UK), Serum Institute of India Pvt. Ltd. (India), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Japan), Daiichi Sankyo (Japan), Panacea Biotec (India), Biological E (India), Bharat Biotech (India), Sinovac Biotech Ltd (China), Incepta Vaccine LTD. (Bangladesh), Valneva SE (France), VBI Vaccines Inc. (US), and Bio Farma (Brazil).

Research Coverage:
The report analyzes the vaccines market and aims at estimating the market size and future growth potential of this market based on various segments such as technology, type, disease indication, route of administration, patient type, and region. The report also includes competitive analysis of the key players in this market along with their company profiles, product and service offerings, recent developments, and key market strategies.

Reasons to Buy the Report
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on the product portfolios of the top players in the vaccines market. The report analyzes the market based on technology, type, disease indication, route of administration, patient type, and region.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in the vaccines market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of vaccines across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in the vaccines market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the vaccines market.

【レポートの目次】

1 Introduction (Page No. – 18)
1.1 Objectives of the Study
1.2 Market Definition
1.3 Market Scope
1.3.1 Market Covered
1.3.2 Years Considered for the Study
1.4 Currency
1.5 Limitations
1.6 Stakeholders

2 Research Methodology (Page No. – 22)
2.1 Research Approach
2.1.1 Secondary Research
2.1.1.1 Key Data From Secondary Sources
2.1.2 Primary Research
2.1.2.1 Key Data From Primary Sources
2.1.2.2 Breakdown of Primaries
2.2 Market Size Estimation
2.3 Data Triangulation Approach
2.4 Market Share Analysis
2.5 Assumptions for the Study

3 Executive Summary (Page No. – 28)

4 Premium Insights (Page No. – 32)
4.1 Vaccines Market Overview
4.2 North America: Vaccines Market, By Technology (2018)
4.3 Geographical Snapshot of the Vaccines Market

5 Market Overview (Page No. – 35)
5.1 Introduction
5.2 Market Dynamics
5.2.1 Drivers
5.2.1.1 High Prevalence of Infectious Diseases
5.2.1.2 Rising Focus on Immunization Programs
5.2.1.3 Growing Government Support for Vaccine Development
5.2.1.4 Increasing Company Initiatives to Enhance Vaccine R&D
5.2.2 Restraints
5.2.2.1 High Cost of Vaccine Development
5.2.3 Opportunities
5.2.3.1 High Growth Prospects in Emerging Markets
5.2.3.2 Focus on Therapeutic Vaccines
5.2.3.3 Use of Adjuvants in Vaccines
5.2.4 Challenges
5.2.4.1 Inadequate Access to Vaccines
5.2.5 Burning Issues
5.2.5.1 Product Recalls

6 Industry Insights (Page No. – 42)
6.1 Regulatory Landscape
6.1.1 North America
6.1.2 Europe
6.1.3 Asia
6.1.4 RoW
6.2 Key Pipeline Products
6.3 New Vaccine Opportunities
6.3.1 HIV
6.3.1.1 HIV Vaccine: Product Pipeline
6.3.1.2 HIV Vaccine: Public-Private Initiatives
6.3.1.3 HIV Vaccine: Funding
6.3.2 Malaria
6.3.2.1 Malaria Vaccine: Product Pipeline
6.3.2.2 Malaria Vaccine: Public-Private Initiatives
6.3.3 Zika
6.3.3.1 Zika Vaccine: Product Pipeline
6.3.3.2 Zika Vaccine: Public-Private Initiatives
6.3.3.3 Zika Vaccine: Funding
6.3.4 Ebola
6.3.4.1 Ebola Vaccine: Product Pipeline
6.3.4.2 Ebola Vaccine: Public-Private Initiatives
6.3.4.3 Ebola Vaccine: Funding
6.3.4.4 Ebola projects funded by EC (2014–2020)

7 Vaccines Market, By Technology (Page No. – 56)
7.1 Introduction
7.2 Conjugate Vaccines
7.2.1 Conjugate Vaccines Hold the Largest Share of the Market
7.3 Inactivated & Subunit Vaccines
7.3.1 Ease of Storage and Transportation have Made Inactivated & Subunit Vaccines Popular
7.4 Live Attenuated Vaccines
7.4.1 Issues in Preserving and Maintaining Live Attenuated Vaccines has Slowed Market Growth
7.5 Recombinant Vaccines
7.5.1 Lack of Post-Vaccination Reactions and Reduced Need for Booster Doses are Driving R&D Into Recombinant Vaccines
7.6 Toxoid Vaccines
7.6.1 Company Initiatives and the Introduction of New Vaccines Will Support Market Growth

8 Vaccines Market, By Type (Page No. – 64)
8.1 Introduction
8.2 Monovalent Vaccines
8.2.1 in 2018, the Monovalent Vaccines Segment Accounted for the Largest Share of the Market
8.3 Multivalent Vaccines
8.3.1 Increasing Initiatives By Companies to Develop New Multivalent Vaccines is Driving the Growth of This Segment

9 Vaccines Market, By Disease Indication (Page No. – 68)
9.1 Introduction
9.2 Pneumococcal Disease
9.2.1 Pneumococcal Disease Segment Accounted for the Largest Share of the Market
9.3 DTP
9.3.1 Increasing Accessibility of DTP Vaccines in Developing Countries to Drive Market Growth
9.4 Influenza
9.4.1 Influenza Vaccines Segment to Grow at the Highest Rate During the Forecast Period
9.5 HPV
9.5.1 Growing Prevalence of HPV Infections to Support Market Growth
9.6 Meningococcal Disease
9.6.1 Rising Incidence of Meningococcal Disease to Support the Growth of This Market Segment
9.7 Polio
9.7.1 Government Initiatives to Support the Growth of This Market Segment
9.8 Hepatitis
9.8.1 High Prevalence of Hepatitis Infections is Driving the Demand for Immunization
9.9 Rotavirus
9.9.1 Rising Incidence of Rotavirus Infections to Drive Market Growth
9.10 MMR
9.10.1 Rising Incidence of Measles, Mumps, and Rubella Will Support the Growth of This Market Segment
9.11 Varicella
9.11.1 Promotion of Immunization Programs to Drive the Demand for Varicella Vaccines
9.12 Herpes Zoster
9.12.1 Herpes Zoster Vaccines to Witness Stable Demand During the Forecast Period
9.13 Other Disease Indications

10 Vaccines Market, By Route of Administration (Page No. – 85)
10.1 Introduction
10.2 Intramuscular and Subcutaneous Administration
10.2.1 Intramuscular and Subcutaneous Administration Accounted for the Largest Share of the Market
10.3 Oral Administration
10.3.1 Possibility of Irritation of the Gastric Mucosa May Limit the Growth of This Segment
10.4 Other Routes of Administration

11 Vaccines Market, By Patient Type (Page No. – 90)
11.1 Introduction
11.2 Pediatric Patients
11.2.1 In 2018, the Pediatric Patients Segment Accounted for the Largest Share of the Market
11.3 Adult Patients
11.3.1 The Adult Patients Segment is Expected to Grow at the Highest CAGR During the Forecast Period

12 Vaccines Market, By Region (Page No. – 94)
12.1 Introduction
12.2 North America
12.2.1 US
12.2.1.1 The US is the Largest Market for Vaccines
12.2.2 Canada
12.2.2.1 High Incidence of Infectious Diseases is Driving the Demand for Vaccines in the Country
12.3 Europe
12.3.1 Germany
12.3.1.1 Significant Investments in R&D to Support Market Growth
12.3.2 UK
12.3.2.1 Launch of New Products to Support Market Growth in the UK in the Coming Years
12.3.3 France
12.3.3.1 Favorable Government Initiatives for Immunization to Support Market Growth in France
12.3.4 Italy
12.3.4.1 Conjugate Vaccines to Account for the Largest Share of the Italian Market
12.3.5 Spain
12.3.5.1 Rising Investments in Vaccine Development By Private Organizations to Support Market Growth in Spain
12.3.6 Rest of Europe
12.4 Asia
12.4.1 Japan
12.4.1.1 Government Initiatives for Increasing the Accessibility of Vaccines to Drive Market Growth in Japan
12.4.2 China
12.4.2.1 Growing Investments in the Biotechnology Sector to Drive Market Growth in China
12.4.3 India
12.4.3.1 Growth of the Biotechnology Sector and Development of New Vaccines to Support Market Growth in India
12.4.4 Rest of Asia
12.5 Rest of the World
12.5.1 Latin America
12.5.2 Other RoW Countries

13 Competitive Landscape (Page No. – 125)
13.1 Overview
13.2 Market Share Analysis
13.3 Competitive Leadership Mapping (Overall Market)
13.3.1 Visionary Leaders
13.3.2 Innovators
13.3.3 Dynamic Differentiators
13.3.4 Emerging Companies
13.4 Competitive Situation and Trends
13.4.1 Agreements, Contracts, and Collaborations
13.4.2 Product Launches and Approvals
13.4.3 Acquisitions
13.4.4 Expansions

14 Company Profiles (Page No. – 132)
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
14.1 Glaxosmithkline PLC
14.2 Pfizer, Inc
14.3 Merck & Co., Inc
14.4 Sanofi Pasteur SA
14.5 CSL Limited
14.6 Emergent Biosolutions, Inc
14.7 Johnson & Johnson
14.8 Astrazeneca
14.9 Serum Institute of India Pvt., LTD
14.10 Bavarian Nordic
14.11 Mitsubishi Tanabe Pharma Corporation
14.12 Daiichi Sankyo Company, Limited
14.13 Panacea Biotec, LTD
14.14 Biological E
14.15 Bharat Biotech
14.16 Other Companies
14.16.1 Sinovac Biotech, LTD
14.16.2 Incepta Vaccine, LTD
14.16.3 Valneva SE
14.16.4 VBI Vaccines Inc
14.16.5 PT Bio Farma (Persero)
*Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

15 Appendix (Page No. – 179)
15.1 Discussion Guide
15.2 Knowledge Store: Marketsandmarkets’ Subscription Portal
15.3 Available Customizations
15.4 Related Reports
15.5 Author Details

List of Tables (107 Tables)

Table 1 Incidence of Infectious Diseases
Table 2 NIH Funding for Vaccine Research, 2013–2018 (USD Million)
Table 3 Immunization Coverage, By Disease, 2016 vs 2018
Table 4 Regulatory Authorities in Europe
Table 5 Regulatory Authorities in Asia
Table 6 Key Pipeline Vaccines
Table 7 Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 8 Cost of Meningococcal Conjugate Vaccines for Pediatric Patients
Table 9 Cost of Meningococcal Conjugate Vaccines for Adult Patients
Table 10 Conjugate Vaccines Market, By Region, 2017–2024 (USD Million)
Table 11 Examples of Inactivated & Subunit Vaccines
Table 12 Inactivated & Subunit Vaccines Market, By Region, 2017–2024 (USD Million)
Table 13 Live Attenuated Vaccines Market, By Region, 2017–2024 (USD Million)
Table 14 Examples of Recombinant Vaccines
Table 15 Recombinant Vaccines Market, By Region, 2017–2024 (USD Million)
Table 16 Toxoid Vaccines Market, By Region, 2017–2024 (USD Million)
Table 17 Vaccines Market, By Type, 2017–2024 (USD Million)
Table 18 Monovalent Vaccines Market, By Region, 2017–2024 (USD Million)
Table 19 Examples of Notable Multivalent Vaccines Available in the Market
Table 20 Multivalent Vaccines Market, By Region, 2017–2024 (USD Million)
Table 21 Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 22 List of Commercially Available Pneumococcal Vaccines in the Market
Table 23 Vaccines Market for Pneumococcal Disease, By Region, 2017–2024 (USD Million)
Table 24 List of Commercially Available DTP Vaccines in the Market
Table 25 Vaccines Market for DTP, By Region, 2017–2024 (USD Million)
Table 26 List of Commercially Available Influenza Vaccines in the Market
Table 27 Vaccines Market for Influenza, By Region, 2017–2024 (USD Million)
Table 28 List of Commercially Available HPV Vaccines in the Market
Table 29 Vaccines Market for HPV, By Region, 2017–2024 (USD Million)
Table 30 List of Commercially Available Meningococcal Disease Vaccines in the Market
Table 31 Vaccines Market for Meningococcal Disease, By Region, 2017–2024 (USD Million)
Table 32 List of Commercially Available Polio Vaccines in the Market
Table 33 Vaccines Market for Polio, By Region, 2017–2024 (USD Million)
Table 34 List of Commercially Available Hepatitis Vaccines in the Market
Table 35 Vaccines Market for Hepatitis, By Region, 2017–2024 (USD Million)
Table 36 List of Commercially Available Rotavirus Vaccines in the Market
Table 37 Vaccines Market for Rotavirus, By Region, 2017–2024 (USD Million)
Table 38 List of Commercially Available MMR Vaccines in the Market
Table 39 Vaccines Market for MMR, By Region, 2017–2024 (USD Million)
Table 40 List of Commercially Available Varicella Vaccines in the Market
Table 41 Vaccines Market for Varicella, By Region, 2017–2024 (USD Million)
Table 42 Vaccines Market for Herpes Zoster, By Region, 2017–2024 (USD Million)
Table 43 List of Commercially Available Vaccines for Other Disease Indications
Table 44 Vaccines Market for Other Disease Indications, By Region, 2017–2024 (USD Million)
Table 45 Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 46 Advantages and Disadvantages of Intramuscular and Subcutaneous Administration
Table 47 Vaccines Market for Intramuscular and Subcutaneous Administration, By Region, 2017–2024 (USD Million)
Table 48 Vaccines Market for Oral Administration, By Region, 2017–2024 (USD Million)
Table 49 Vaccines Market for Other Routes of Administration, By Region, 2017–2024 (USD Million)
Table 50 Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 51 Vaccines Market for Pediatric Patients, By Region, 2017–2024 (USD Million)
Table 52 North America: Vaccines Market for Pediatric Patients, By Country, 2017–2024 (USD Million)
Table 53 Vaccines Market for Adult Patients, By Region, 2017–2024 (USD Million)
Table 54 North America: Vaccines Market for Adult Patients, By Country, 2017–2024 (USD Million)
Table 55 Vaccines Market, By Region, 2017–2024 (USD Million)
Table 56 North America: Vaccines Market, By Country, 2017–2024 (USD Million)
Table 57 North America: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 58 North America: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 59 North America: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 60 North America: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 61 North America: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 62 Number of New Infectious Disease Cases in the Us, 2017
Table 63 US: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 64 US: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 65 Number of New Infectious Disease Cases in Canada
Table 66 Canada: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 67 Canada: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 68 Europe: Vaccines Market, By Country, 2017–2024 (USD Million)
Table 69 Europe: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 70 Europe: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 71 Europe: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 72 Europe: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 73 Europe: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 74 Germany: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 75 UK: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 76 France: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 77 Italy: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 78 Spain: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 79 RoE: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 80 Asia: Health Expenditure Per Capita, By Country, 2000, 2014, and 2016 (USD)
Table 81 Asia: Vaccines Market, By Country, 2017–2024 (USD Million)
Table 82 Asia: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 83 Asia: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 84 Asia: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 85 Asia: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 86 Asia: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 87 Disease Incidence in Japan, 2016–2018
Table 88 Japan: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 89 China: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 90 India: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 91 RoA: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 92 RoW: Vaccines Market, By Region, 2017–2024 (USD Million)
Table 93 RoW: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 94 RoW: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 95 RoW: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 96 RoW: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 97 RoW: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 98 Latin America: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 99 Latin America: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 100 Latin America: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 101 Latin America: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 102 Latin America: Vaccines Market, By Patient Type, 2017–2024 (USD Million)
Table 103 Other RoW Countries: Vaccines Market, By Technology, 2017–2024 (USD Million)
Table 104 Other RoW Countries: Vaccines Market, By Type, 2017–2024 (USD Million)
Table 105 Other RoW Countries: Vaccines Market, By Disease Indication, 2017–2024 (USD Million)
Table 106 Other RoW Countries: Vaccines Market, By Route of Administration, 2017–2024 (USD Million)
Table 107 Other RoW Countries: Vaccines Market, By Patient Type, 2017–2024 (USD Million)

List of Figures (35 Figures)

Figure 1 Vaccines Market Segmentation
Figure 2 Research Design
Figure 3 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 4 Bottom-Up Approach
Figure 5 Top-Down Approach
Figure 6 Data Triangulation Methodology
Figure 7 Vaccines Market, By Technology, 2019 vs 2024 (USD Million)
Figure 8 Vaccines Market, By Type, 2019 vs 2024 (USD Million)
Figure 9 Vaccines Market, By Disease Indication, 2019 vs 2024 (USD Million)
Figure 10 Vaccines Market, By Route of Administration, 2019 vs 2024 (USD Million)
Figure 11 Vaccines Market, By Patient Type, 2019 vs 2024 (USD Million)
Figure 12 Geographical Snapshot of the Vaccines Market
Figure 13 High Prevalence of Diseases and Rising Focus on Immunization Programs are Driving Market Growth
Figure 14 Conjugate Vaccines Accounted for the Largest Share of the North American Vaccines Market in 2018
Figure 15 Asia to Witness the Highest Growth in the Vaccines Market From 2019 to 2024
Figure 16 Vaccines Market: Drivers, Restraints, Opportunities, and Challenges
Figure 17 Regulatory Approval Process for Vaccines
Figure 18 North America Will Continue to Dominate the Vaccines Market in 2024
Figure 19 North America: Vaccines Market Snapshot
Figure 20 Europe: Vaccines Market Snapshot
Figure 21 Asia: Vaccines Market Snapshot
Figure 22 Vaccines Market Share Analysis, By Key Player, 2018 127
Figure 23 Competitive Leadership Mapping: Vaccines Market 130
Figure 24 Glaxosmithkline PLC.: Company Snapshot (2018)
Figure 25 Pfizer, Inc.: Company Snapshot (2018)
Figure 26 Merck & Co., Inc.: Company Snapshot (2018)
Figure 27 Sanofi Pasteur SA: Company Snapshot (2018)
Figure 28 CSL Limited: Company Snapshot (2018)
Figure 29 Emergent Biosolutions, Inc.: Company Snapshot (2018)
Figure 30 Johnson & Johnson: Company Snapshot (2018)
Figure 31 Astrazeneca: Company Snapshot (2018)
Figure 32 Bavarian Nordic: Company Snapshot (2018)
Figure 33 Mitsubishi Tanabe Pharma Corporation: Company Snapshot (2018)
Figure 34 Daiichi Sankyo Company: Company Snapshot (2018)
Figure 35 Panacea Biotec: Company Snapshot (2018)



★調査レポート[ワクチンの世界市場予測：技術別（生、トキソイド、組換え）、疾患別（肺炎球菌、インフルエンザ、DTP、ロタウイルス、TT、ポリオ、MMR、水痘、デング熱、結核、帯状疱疹、狂犬病）、経路別（IM、SC、ID、経口）、患者別（小児、成人）、種類別] ( Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024 / PH 6528) 販売に関する免責事項
[ワクチンの世界市場予測：技術別（生、トキソイド、組換え）、疾患別（肺炎球菌、インフルエンザ、DTP、ロタウイルス、TT、ポリオ、MMR、水痘、デング熱、結核、帯状疱疹、狂犬病）、経路別（IM、SC、ID、経口）、患者別（小児、成人）、種類別] ( Vaccines Market by Technology (Live, Toxoid, Recombinant), Disease (Pneumococcal, Influenza, DTP, Rotavirus, TT, Polio, MMR, Varicella, Dengue, TB, shingles, Rabies), Route (IM, SC, ID, Oral), Patient (Pediatric, Adult), Type - Global Forecast to 2024 / PH 6528) についてEメールでお問い合わせ

※関連データはありません。


◆H&Iグローバルリサーチ株式会社のお客様（例）◆